How to buy AtriCure stock (ATRC)

AtriCure is a medical instruments & supplies business based in the US. AtriCure shares (ATRC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $30.50 – an increase of 1.5% over the previous week. AtriCure employs 1,200 staff and has a trailing 12-month revenue of around $447.6 million.

Our top picks for where to buy AtriCure stock

Buy AtriCure stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AtriCure stock price (NASDAQ: ATRC)

Use our graph to track the performance of ATRC stocks over time.

AtriCure shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$30.50
52-week range	$18.94 - $39.05
50-day moving average more info button	$32.93
200-day moving average more info button	$27.02
Wall St. target price	$45.11
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.83

Is it a good time to buy AtriCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AtriCure price performance over time

Historical closes compared with the close of $30.5 from 2024-12-24

1 week (2024-12-19)	1.50%
1 month (2024-11-26)	-14.78%
3 months (2024-09-26)	7.32%
6 months (2024-06-26)	32.61%

1 year (2023-12-26)	-18.25%
2 years (2022-12-23)	-30.19%
3 years (2021-12-23)	73.36
5 years (2019-12-26)	32.14

AtriCure financials

Revenue TTM	$447.6 million
Gross profit TTM	$245.9 million
Return on assets TTM	-3.51%
Return on equity TTM	-8.39%
Profit margin	-8.7%
Book value	$9.54
Market Capitalization more info button	$1.5 billion

TTM: trailing 12 months

AtriCure share dividends

We're not expecting AtriCure to pay a dividend over the next 12 months.

AtriCure share price volatility

Over the last 12 months, AtriCure's shares have ranged in value from as little as $18.94 up to $39.045. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 1.408. This would suggest that AtriCure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AtriCure overview

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Frequently asked questions

null
What percentage of AtriCure is owned by insiders or institutions?
Currently 3.182% of AtriCure shares are held by insiders and 105.562% by institutions. How many people work for AtriCure?
Latest data suggests 1,200 work at AtriCure. When does the fiscal year end for AtriCure?
AtriCure's fiscal year ends in December. Where is AtriCure based?
AtriCure's address is: 7555 Innovation Way, Mason, OH, United States, 45040 What is AtriCure's ISIN number?
AtriCure's international securities identification number is: US04963C2098 What is AtriCure's CUSIP number?
AtriCure's Committee on Uniform Securities Identification Procedures number is: 04963C209